Japan Non-invasive Prenatal Diagnostics Market Size & Outlook
Related Markets
Japan non-invasive prenatal diagnostics market highlights
- The Japan non-invasive prenatal diagnostics market generated a revenue of USD 165.7 million in 2020 and is expected to reach USD 335.3 million by 2027.
- The Japan market is expected to grow at a CAGR of 10.6% from 2021 to 2027.
- In terms of segment, 13-24 weeks was the largest revenue generating gestation period in 2020.
- 0-12 weeks is the most lucrative gestation period segment registering the fastest growth during the forecast period.
Non-invasive prenatal diagnostics market data book summary
| Market revenue in 2020 | USD 165.7 million |
| Market revenue in 2027 | USD 335.3 million |
| Growth rate | 10.6% (CAGR from 2020 to 2027) |
| Largest segment | 13-24 weeks |
| Fastest growing segment | 0-12 weeks |
| Historical data | 2015 - 2019 |
| Base year | 2020 |
| Forecast period | 2021 - 2027 |
| Quantitative units | Revenue in USD million |
| Market segmentation | 0-12 weeks, 13-24 weeks, 25-36 weeks |
| Key market players worldwide | CooperSurgical, Natera Inc, Eurofins Scientific SE, Illumina Inc, Centogene NV Ordinary Shares, Myriad Genetics Inc, Roche, Qiagen NV, Labcorp Holdings Inc, Biora Therapeutics, Quest Diagnostics Inc, Medgene Labs |
Other key industry trends
- In terms of revenue, Japan accounted for 4.9% of the global non-invasive prenatal diagnostics market in 2020.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2027.
- In Asia Pacific, China non-invasive prenatal diagnostics market is projected to lead the regional market in terms of revenue in 2027.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 540.3 million by 2027.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Non-invasive Prenatal Diagnostics Market Scope
Non-invasive Prenatal Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Medgene Labs | View profile | 11-50 | Sioux Falls, South Dakota, United States, North America | https://medgenelabs.com |
| CooperSurgical | View profile | 501-1000 | Trumbull, Connecticut, United States, North America | http://www.coopersurgical.com |
| Biora Therapeutics | View profile | 51-100 | Carlsbad, California, United States, North America | https://www.bioratherapeutics.com/ |
| Centogene NV Ordinary Shares | View profile | 493 | Am Strande 7, Rostock, MV, Germany, 18055 | https://www.centogene.com |
| Roche | View profile | 10001+ | Basel, Basel-Stadt, Switzerland, Europe | http://www.roche.com |
| Labcorp Holdings Inc | View profile | 67000 | 358 South Main Street, Burlington, NC, United States, 27215 | https://www.labcorp.com |
| Natera Inc | View profile | 3293 | 13011 McCallen Pass, Building A Suite 100, Austin, TX, United States, 78753 | https://www.natera.com |
| Myriad Genetics Inc | View profile | 2700 | 320 Wakara Way, Salt Lake City, UT, United States, 84108 | https://www.myriad.com |
| Eurofins Scientific SE | View profile | 61798 | 23 Val Fleuri, Luxembourg, Luxembourg, L-1526 | https://www.eurofins.com |
| Qiagen NV | View profile | 5900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | https://www.qiagen.com |
| Illumina Inc | View profile | 9300 | 5200 Illumina Way, San Diego, CA, United States, 92122 | https://www.illumina.com |
| Quest Diagnostics Inc | View profile | 48000 | 500 Plaza Drive, Secaucus, NJ, United States, 07094 | https://www.questdiagnostics.com |
Japan non-invasive prenatal diagnostics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to non-invasive prenatal diagnostics market will help companies and investors design strategic landscapes.
13-24 weeks was the largest segment with a revenue share of 45.81% in 2020. Horizon Databook has segmented the Japan non-invasive prenatal diagnostics market based on 0-12 weeks, 13-24 weeks, 25-36 weeks covering the revenue growth of each sub-segment from 2015 to 2027.
Unlike other developed nations, NIPT is only available to high-risk pregnant women in Japan. For example, women with abnormalities visible in ultrasonography. In April 2015, Japan concluded a nationwide project for demonstration of the safety and efficacy of NGS non-invasive prenatal aneuploidy testing.
The healthcare and clinical research service providers in Japan have been integrating NGS technologies for the past couple of years and are expected to account for a considerable share of Asia Pacific market. Presence of increasing average maternal age in the country is driving the demand for non-invasive prenatal screening, which is positively influencing the market growth.
For instance, according to Journal of Woman’s Reproductive Health, in 2018, 28.5% Japanese women gave birth over the age of 35, which is considered high-risk pregnancy. However, owing to cultural aspects, the number of tests performed is still low in the country.
Reasons to subscribe to Japan non-invasive prenatal diagnostics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Japan non-invasive prenatal diagnostics market databook
-
Our clientele includes a mix of non-invasive prenatal diagnostics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan non-invasive prenatal diagnostics market, including forecasts for subscribers. This country databook contains high-level insights into Japan non-invasive prenatal diagnostics market from 2015 to 2027, including revenue numbers, major trends, and company profiles.
Partial client list
Japan noninvasive prenatal diagnostics market size, by gestation period, 2015-2027 (US$M)
Japan Non-invasive Prenatal Diagnostics Market Share, 2020 & 2027 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
